Donation Activities and Product Integrity in Unrelated Donor Allogeneic Hematopoietic Transplantation: Experience of the National Marrow Donor Program

Number of subsequent (second, third, fourth) NMDP-facilitated transplants, by transplant year.

Placement of central lines according to anatomic location for donors undergoing 1-day and 2-day PBSC collections in male and female donors. For donors scheduled for a 1-day collection, the frequency of central line placement was similar in the internal jugular and femoral locations, each of which occurred more than twice as frequently as placement in subclavian or other locations. In contrast, the frequency of femoral line placement was less common, whereas the frequency of internal jugular and subclavian vein placement was more common in donors scheduled to undergo a 2-day collection.

Frequency of male and female donors receiving central venous catheter placement, by year of collection. The rate of line placement has remained stable since the year 2000 for both male and female donors, at between 18% and 24% for females, and between 2% and 5% for males.

Peripheral blood CD34⁺ cell counts in female and male donors following administration of filgrastim subcutaneously for 5 days at a targeted dose of 10 to 12 μg/kg/day. In both female and male donors, the CD34⁺ cell count increased with increasing donor weight (higher total amounts of filgrastim). Higher responses were also observed in male compared to female donors with body weights of <80 kg.

Apheresis PBSC collection efficiency, plotted as the CD34⁺ cell yield per liter, processed versus the CD34⁺ cell concentration in peripheral blood at the beginning of apheresis. The product yield was highly correlated with the pre-apheresis CD34⁺ cell count. The collection efficiency was 38%, indicating that the product yield increased by 0.38 × 10⁶/L processed for every 1 × 10⁶ cell/L increase in the pre-apheresis CD34⁺ concentration.